MedTrace Logo

Portal Vein Resection in Pancreatic Neuroendocrine Tumours

NCT04336839 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2020-04-07

No results posted yet for this study

Summary

The limited evidence on the value of portal vein resection in patients with borderline resectable and/or locally advanced PanNENs is an incentive to carry out a retrospective multicentre study amongst centres with specific interest in the management of PanNENs and with experience on vascular reconstruction. Unlike previous studies on pancreatic cancer, it is more difficult to standardise the comparative parameters as the definition of borderline resectable disease has never been published for PanNENs. Similarly, different histological classifications make impossible to collect data exclusively on T3 tumours. Therefore, we aim to compare the short and long-term outcomes (including the impact of the histological depth of vascular invasion on survival) between patients undergoing standard PD and PD with portal vein resection for PanNENs, (regardless of T stage), by collecting and analysing retrospective data in this single centre study

Conditions

Interventions

PROCEDURE

Portal vein resection / reconstruction

Portal vein resection and reconstruction, with or without concommitant arterial resection

Sponsors & Collaborators

  • Royal Free Hospital NHS Foundation Trust

    lead OTHER

Principal Investigators

  • Giuseppe K Fusai, MD MS · Royal Free London NHS Foundation Trust & University College London

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-05-01
Primary Completion
2020-06-15
Completion
2020-08-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04336839 on ClinicalTrials.gov